PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21410334-7	2011	Also, travoprost/timolol BAK induced less apoptosis than latanoprost/timolol BAK (P<0.0001).	Travoprost	6-16	BCL2 antagonist/killer 1	Homo sapiens	25-28	
21410334-5	2011	RESULTS: The NR and AB assays demonstrated that cells incubated with travoprost/timolol PQ had significantly better viability than cells incubated with latanoprost/timolol BAK, travoprost/timolol BAK, BAK 0.015%, and BAK 0.020% (P<0.0001 for all).	Travoprost	69-79	BCL2 antagonist/killer 1	Homo sapiens	196-199	
21410334-5	2011	RESULTS: The NR and AB assays demonstrated that cells incubated with travoprost/timolol PQ had significantly better viability than cells incubated with latanoprost/timolol BAK, travoprost/timolol BAK, BAK 0.015%, and BAK 0.020% (P<0.0001 for all).	Travoprost	69-79	BCL2 antagonist/killer 1	Homo sapiens	196-199	
21410334-5	2011	RESULTS: The NR and AB assays demonstrated that cells incubated with travoprost/timolol PQ had significantly better viability than cells incubated with latanoprost/timolol BAK, travoprost/timolol BAK, BAK 0.015%, and BAK 0.020% (P<0.0001 for all).	Travoprost	69-79	BCL2 antagonist/killer 1	Homo sapiens	196-199	
21410334-6	2011	As assessed with YO-PRO-1 and Hoechst 33342 relative to cell viability determined with NR or AB, travoprost/timolol PQ produced significantly less apoptosis than travoprost/timolol BAK and latanoprost/timolol BAK and their respective BAK concentrations alone (P<0.0001 for all).	Travoprost	97-107	BCL2 antagonist/killer 1	Homo sapiens	209-212	
21410334-6	2011	As assessed with YO-PRO-1 and Hoechst 33342 relative to cell viability determined with NR or AB, travoprost/timolol PQ produced significantly less apoptosis than travoprost/timolol BAK and latanoprost/timolol BAK and their respective BAK concentrations alone (P<0.0001 for all).	Travoprost	97-107	BCL2 antagonist/killer 1	Homo sapiens	209-212	
25967526-0	2016	Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost.	Travoprost	23-33	BCL2 antagonist/killer 1	Homo sapiens	137-140	
21410334-10	2011	In contrast, release of superoxide anions (hydroethidine method) after incubation with travoprost/timolol BAK was not significantly different from incubation with latanoprost/timolol BAK or travoprost/timolol PQ.	Travoprost	87-97	BCL2 antagonist/killer 1	Homo sapiens	106-109